Year 2 Prime Therapeutics’ leading research shows 1 in 12 remain on a GLP-1 drug for obesity at three years. Findings also show improved persistence with high-potency, obesity-approved GLP-1...

Following real-world analysis of GLP-1 drugs for weight loss, Prime/Magellan Rx releases new video about GLP-1 research

New report details the latest on GLP-1s

publications Spring 2025 Prime Therapeutics Report March 21, 2025 The Prime Therapeutics Report is your source for innovative managed care strategies, trends and updates. Our cover story (Page 18)...

Maryam Tabatabai, PharmD, associate vice president of clinical information, offers predictions about forthcoming drug approvals, the latest on a new voucher pilot, updated biosimilar guidance and more

Jessica Johnson, clinical consultant at Prime Therapeutics, shares more about common GLP-1 fraud schemes

GLP-1 year two cost effectiveness study abstract

Real-world study of GLP-1 patients continues to deliver leading insights

Findings also show improved persistence with high-potency, obesity-approved GLP-1 products

publications The evolution of GLP-1s July 31, 2025 Prime's clinical experts share their perspectives on developing a holistic, individualized strategy to capitalize on opportunities and improve...

Prime's recent analysis shows that patients with obesity stopped using a GLP-1 medication within the first few years of treatment.

Among the key findings from the study — among 4,066 members, Prime/MRx found 1 in 3 stayed on their GLP-1 and 27% took their medication as intended

cover image for the 2025 Spring Prime Therapeutics Report Autoimmune management: Updates and challenges Prime Therapeutics /spring-2025-prime-therapeutics-report The Prime Therapeutics Report is...

Forbes: Injectable glucagon-like peptide-1 agonists, or GLP-1s, were first approved as diabetes medications 20 years ago

David Lassen, vice president of pharmacy clinical services, and Marci Chodroff, vice president and medical director at Prime Therapeutics, share more about the latest GLP-1 insights from ongoing...

BioSpace: While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that myriad variables are causing patients to stop treatment

Jessica Johnson, clinical consultant at Prime's Special Investigations Unit, shares how to identify fake GLP-1s

Ben Urick, senior director of health outcomes, and Landon Marshall, health outcomes research principal, share more about their educational session and research poster on GLP-1s

In this second of a two-part episode of the Pharmacy Friends podcast, industry experts discuss clinical evidence, drug information and appropriate patient selection for GLP-1 use

Managed Healthcare Executive: A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member,...